July 13, 2011ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)
Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction
Key result
Higher procollagen type I amino-terminal peptide is linked to ~9% greater death or CV hospitalization risk per 10-μg/L.
- HR 1.09
- 95% CI 1.052-1.13
- P<0.0001
- n=334
Why the study?
Are baseline peripheral collagen markers associated with death and hospitalization in patients with HFPEF?
Population
334 patients with heart failure with preserved ejection fraction (HFPEF)
Comparison
Irbesartan 300 mg/day vs Placebo
Design
Cohort, randomization to placebo or irbesartan
Authors
Discussion
Loading...
Member takes
Implication
Baseline PINP associated with worse HFpEF outcomes; leaves open independent prognostic value after multivariable adjustment.
Study Design
Type
RCT (n=334)
Randomization
Randomized
Structured PICO
Are baseline peripheral collagen markers associated with death and hospitalization in patients with HFPEF?
P
Population
334 patients with heart failure and preserved ejection fraction (HFPEF) randomized to irbesartan or placebo, with collagen markers measured at baseline and 6 months.
I
Intervention
Irbesartan 300 mg/day
C
Comparator
Placebo
O
Outcome
Composite of all-cause death and hospitalization for prespecified cardiovascular causescomposite
Main Result
Hazard Ratio: 1.09 (95% CI 1.052–1.13)
p-value: p=<0.0001
Peripheral collagen turnover markers are associated with adverse outcomes in HFpEF on univariable but not multivariable analysis, suggesting they may not be independent prognostic markers.
Cite This Study
Krum et al. (2011) conducted an RCT in Heart failure with preserved ejection fraction (HFPEF) (n=334). Irbesartan vs. Placebo was evaluated on All-cause death and hospitalization for prespecified cardiovascular causes (HR 1.09, 95% CI 1.052-1.13, p=<0.0001). Each 10-μg/L increase in baseline procollagen type I amino-terminal peptide was associated with increased risk of death or cardiovascular hospitalization (HR 1.09; 95% CI 1.052-1.13; P<0.0001).